MX2015010983A - Inhibidores de tirosina-cinasa de bruton. - Google Patents
Inhibidores de tirosina-cinasa de bruton.Info
- Publication number
- MX2015010983A MX2015010983A MX2015010983A MX2015010983A MX2015010983A MX 2015010983 A MX2015010983 A MX 2015010983A MX 2015010983 A MX2015010983 A MX 2015010983A MX 2015010983 A MX2015010983 A MX 2015010983A MX 2015010983 A MX2015010983 A MX 2015010983A
- Authority
- MX
- Mexico
- Prior art keywords
- compounds
- btk
- bruton
- inhibitors
- tyrosine kinase
- Prior art date
Links
- 102000001714 Agammaglobulinaemia Tyrosine Kinase Human genes 0.000 title 1
- 108010029445 Agammaglobulinaemia Tyrosine Kinase Proteins 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 4
- 230000000694 effects Effects 0.000 abstract 2
- 208000023275 Autoimmune disease Diseases 0.000 abstract 1
- 230000001594 aberrant effect Effects 0.000 abstract 1
- 210000003719 b-lymphocyte Anatomy 0.000 abstract 1
- 239000003085 diluting agent Substances 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000027866 inflammatory disease Diseases 0.000 abstract 1
- 230000002757 inflammatory effect Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 1
- 230000035755 proliferation Effects 0.000 abstract 1
- 206010039073 rheumatoid arthritis Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Pulmonology (AREA)
- Pain & Pain Management (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Epidemiology (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Esta solicitud describe compuestos de acuerdo con la fórmula genérica (I) ; en donde todas las variables se definen como de describe en la presente, que inhiben BTK. Los compuestos descritos en la presente son útiles para modular la actividad de BTK y para tratar enfermedades asociadas con actividad excesiva de BTK. Los compuestos son además útiles para tratar enfermedades inflamatorias y autoinmunitarias asociadas con proliferación anormal de células B, tal como artritis reumatoide. También se describen composiciones que contienen compuestos de la fórmula I y al menos un portador diluyente o excipiente.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361772954P | 2013-03-05 | 2013-03-05 | |
| PCT/EP2014/054018 WO2014135474A1 (en) | 2013-03-05 | 2014-03-03 | Inhibitors of bruton's tyrosine kinase |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2015010983A true MX2015010983A (es) | 2015-10-26 |
Family
ID=50190455
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2015010983A MX2015010983A (es) | 2013-03-05 | 2014-03-03 | Inhibidores de tirosina-cinasa de bruton. |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US9663494B2 (es) |
| EP (1) | EP2964642B1 (es) |
| JP (1) | JP2016510051A (es) |
| KR (1) | KR101763504B1 (es) |
| CN (1) | CN105143215B (es) |
| BR (1) | BR112015021806A2 (es) |
| CA (1) | CA2903137C (es) |
| HK (1) | HK1218416A1 (es) |
| MX (1) | MX2015010983A (es) |
| RU (1) | RU2015141360A (es) |
| WO (1) | WO2014135474A1 (es) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2920162B1 (en) * | 2012-11-16 | 2017-04-19 | F. Hoffmann-La Roche AG | Inhibitors of bruton's tyrosine kinase |
| AU2016341884B2 (en) | 2015-10-19 | 2021-06-10 | Board Of Regents, The University Of Texas System | Piperazinyl norbenzomorphan compounds and methods for using the same |
| EP3448520A4 (en) * | 2016-04-29 | 2020-07-29 | Board Of Regents, The University Of Texas System | SIGMA RECEIVER BINDERS |
| JP7535949B2 (ja) | 2018-02-19 | 2024-08-19 | グアンジョウ・ルペン・ファーマシューティカル・カンパニー・リミテッド | Ｂｔｋおよびその変異体の阻害剤 |
| AU2019253510B2 (en) | 2018-04-13 | 2023-08-10 | Cancer Research Technology Limited | BCL6 inhibitors |
| GB201914860D0 (en) | 2019-10-14 | 2019-11-27 | Cancer Research Tech Ltd | Inhibitor compounds |
| CN117897388A (zh) * | 2020-12-20 | 2024-04-16 | 广州麓鹏制药有限公司 | Btk蛋白降解剂 |
| JP2024503237A (ja) * | 2020-12-20 | 2024-01-25 | グアンジョウ・ルペン・ファーマシューティカル・カンパニー・リミテッド | Ｂｔｋ分解誘導薬 |
| WO2022140246A1 (en) | 2020-12-21 | 2022-06-30 | Hangzhou Jijing Pharmaceutical Technology Limited | Methods and compounds for targeted autophagy |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2701275C (en) * | 2007-10-23 | 2016-06-21 | F. Hoffmann-La Roche Ag | Kinase inhibitors |
| JP5259739B2 (ja) * | 2008-02-05 | 2013-08-07 | エフ．ホフマン−ラ ロシュ アーゲー | 新規ピリジノン及びピリダジノン |
| US8299077B2 (en) | 2009-03-02 | 2012-10-30 | Roche Palo Alto Llc | Inhibitors of Bruton's tyrosine kinase |
| ES2513915T3 (es) * | 2009-04-24 | 2014-10-27 | F. Hoffmann-La Roche Ag | Inhibidores de la tirosina quinasa de Bruton |
| AR082590A1 (es) * | 2010-08-12 | 2012-12-19 | Hoffmann La Roche | Inhibidores de la tirosina-quinasa de bruton |
| RU2015111133A (ru) * | 2012-09-13 | 2016-11-10 | Ф. Хоффманн-Ля Рош Аг | Ингибиторы тирозинкиназы брутона |
| CN104968346B (zh) * | 2012-11-30 | 2017-06-27 | 弗·哈夫曼-拉罗切有限公司 | 酪氨酸蛋白激酶抑制剂 |
-
2014
- 2014-03-03 EP EP14707402.5A patent/EP2964642B1/en not_active Not-in-force
- 2014-03-03 WO PCT/EP2014/054018 patent/WO2014135474A1/en not_active Ceased
- 2014-03-03 US US14/768,705 patent/US9663494B2/en not_active Expired - Fee Related
- 2014-03-03 RU RU2015141360A patent/RU2015141360A/ru not_active Application Discontinuation
- 2014-03-03 MX MX2015010983A patent/MX2015010983A/es unknown
- 2014-03-03 BR BR112015021806A patent/BR112015021806A2/pt not_active IP Right Cessation
- 2014-03-03 CA CA2903137A patent/CA2903137C/en not_active Expired - Fee Related
- 2014-03-03 KR KR1020157026057A patent/KR101763504B1/ko not_active Expired - Fee Related
- 2014-03-03 CN CN201480011806.9A patent/CN105143215B/zh not_active Expired - Fee Related
- 2014-03-03 JP JP2015560642A patent/JP2016510051A/ja active Pending
- 2014-03-03 HK HK16106435.2A patent/HK1218416A1/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US9663494B2 (en) | 2017-05-30 |
| KR101763504B1 (ko) | 2017-07-31 |
| CA2903137C (en) | 2017-07-18 |
| EP2964642A1 (en) | 2016-01-13 |
| CA2903137A1 (en) | 2014-09-12 |
| BR112015021806A2 (pt) | 2017-07-18 |
| CN105143215A (zh) | 2015-12-09 |
| KR20150119944A (ko) | 2015-10-26 |
| RU2015141360A (ru) | 2017-04-10 |
| HK1218416A1 (zh) | 2017-02-17 |
| JP2016510051A (ja) | 2016-04-04 |
| CN105143215B (zh) | 2017-12-08 |
| WO2014135474A1 (en) | 2014-09-12 |
| EP2964642B1 (en) | 2017-11-15 |
| US20150376166A1 (en) | 2015-12-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12013502379A1 (en) | Inhibitors of bruton's tyrosine kinase | |
| PH12014500128A1 (en) | Inhibitors of bruton's tyrosine kinase | |
| WO2014064131A3 (en) | Inhibitors of bruton's tyrosine kinase | |
| MX2015010983A (es) | Inhibidores de tirosina-cinasa de bruton. | |
| MX2015010466A (es) | Inhibidores de tirosina cinasa de bruton. | |
| ZA202401324B (en) | Tyrosine kinase inhibitors | |
| MX339583B (es) | Inhibidores de tirosina cinasa de bruton. | |
| MX2021003478A (es) | Compuestos utiles como inhibidores de cinasa. | |
| EA201390207A1 (ru) | Ингибиторы тирозинкиназы брутона | |
| PH12018500587A1 (en) | Pyrazolopyrimidine derivatives as btk inhibitors for the treatment of cancer | |
| PH12016500531B1 (en) | Compound inhibiting activities of btk and/or jak3 kinases | |
| TW201613896A (en) | Novel 2,5-substituted pyrimidines | |
| MX2015007291A (es) | Derivados de tiazol como inhibidores de la tirosina cinasa de bruton. | |
| MX374758B (es) | Inhibidores de tirosina cinasa de bruton. | |
| MX370010B (es) | Inhibidores de tirosina cinasa de bruton. | |
| MX2015013685A (es) | Inhibidores de tirosina cinasa de bruton. | |
| MX374759B (es) | Inhibidores de tirosina cinasa de bruton. | |
| MX2015010820A (es) | Inhibidores de tirosina cinasa de bruton. | |
| PH12013500162A1 (en) | Inhibitors of bruton`s tyrosine kinase |